Entrance of the EAACI Congress 2025, SEC in Glasgow Entrance of the EAACI Congress in the SEC located in Glasgow 苏黎世, July 17, 2025 (GLOBE NEWSWIRE) -- 2025 年 EAACI 大会吸引了超 7600 名代表参会，其不仅因规模成为焦点，更因领导层传递的有力信息备受关注。 如今，在格拉斯哥大会闭幕一个月之际，EAACI 高层正分享他们对此次大会的回顾，称其为该领域的一个转折点。 大会于 6 月 13 日至 16 日在苏格兰活动园区 (Scottish Event Campus) 举行，主题是“打破过敏、哮喘和临床免疫学的界限：整合地球健康，共创可持续未来”。 “今年的大会是一个转折点，” EAACI 主席 Maria Torres 教授表示。 “我们正迈入一个科学创新、医疗公平与环境健康必须协同推进的时代。” 大会日程包含超过 250 小时的讲座、研讨会和专题讨论会，涵盖药物过敏、T2 型炎症、儿童哮喘及遗传性血管性水肿等领域的突破性进展。 主席专题讨论 ...

来源：中国新闻网 根据会前征集到的200个前沿科学问题，大会现场设置25个专题研讨，重点聚焦创新材料、宇宙实验 室、生态农业、类脑智能、气候变化与健康、中西抗癌互鉴、合成生物学等众多领域，涵盖了生命科 学、地球科学、材料科学、医学、能源科学和交叉科学等多个学科方向。百余名特邀嘉宾针对问题发表 观点，并和所有参会人员展开互动交流和前瞻思辨，凝聚智慧，碰撞观点，达成共识，落地转化。 如中国科学院院士、复旦大学科学技术研究院院长彭慧胜在主旨演讲中表示，材料创新推动了社会不断 进步，新材料推动了中国多个战略产业的革命性发展。中国科学院国家天文台研究员刘继峰则结合自身 研究分享了宇宙实验室的最新进展及未来展望，诚邀各学科的专家学者一起开启黑洞研究的新篇章。随 后在聚焦创新材料和宇宙实验室进行的圆桌论坛第一场讨论中，与会院士、专家纷纷结合自身研究领域 展开学科交叉研究可能性的深入讨论。 中新网长沙7月12日电 (记者 刘双双)2025前沿科学创新大会12日在湖南长沙举办，开幕式上主办方特别 发布"人类面临的前100大挑战"全球问题征集邀请，联合所有学科领域的科学家，从多学科视角洞察可 持续发展亟需解决的关键问题，呼吁科学 ...

Core Viewpoint - Huaxi Biological's 2024 annual report indicates significant growth in both domestic and international raw material business revenues, with a focus on expanding overseas operations and enhancing product certifications to capture market opportunities [1][2]. Group 1: Revenue Growth - In 2024, the raw material business achieved revenue of 1.236 billion yuan, with domestic revenue at 628 million yuan (up 2.61%) and international revenue at 608 million yuan (up 17.60%) [1]. - The sales volume of the Furst brand HA reached 143.12 tons (up approximately 22%), while Huaxi Biological brand HA sales volume reached 261 tons (up approximately 13%) [3]. - The medical terminal business generated revenue of 1.44 billion yuan, a year-on-year increase of 32.03%, driven by a 43.57% increase in skin-related medical products [3]. Group 2: International Expansion - The company has deepened its overseas business layout by localizing operations, including hiring foreign sales teams and participating in international raw material exhibitions [1]. - In 2024, the company participated in 27 overseas exhibitions and held 8 seminars, establishing connections with various international associations [1]. Group 3: Sales Strategy - The sales strategy involves a two-phase approach: initially targeting customers with the Furst brand for cost-effective products, followed by introducing Huaxi Biological's high-end products to meet upgraded customer needs [2]. - The direct sales channel accounted for over 65% in 2023 and is expected to exceed 75% in 2024, with a goal of reaching 80% by 2025 [4]. Group 4: Inventory Management - The company has implemented a plan to manage inventory effectively, with a significant reduction in over one-year-old inventory from 185 million yuan to 112 million yuan by the end of 2024 [5]. - The inventory turnover rate for Huaxi Biological was 1.11, slightly lower than some peers, attributed to its self-production model [6][7]. Group 5: Market Positioning - The company’s online sales accounted for 43.92% of revenue, indicating a strong digital presence compared to competitors [7][8]. - The overseas sales revenue accounted for 16.56% of total revenue, highlighting the company's commitment to international markets [8].

转自：北京日报客户端 立足产学研资源禀赋优势，打造首都发展新增长极——6月25日，HICOOL 2025全球创业大赛昌平赛区 启动。未来三天，来自全球的250余个生物技术/健康服务赛道优质项目将展开激烈角逐，项目覆盖基因 治疗、细胞工程、疫苗研发、血液制品、蛋白质合成、微生物技术、健康管理、数字医疗、康养服务及 医美科技等前沿领域。 此外，为加速项目落地，昌平区特设"人才会客厅"，由昌平区人才工作局、区投促中心、区科委、区经 信局、未来科学城管委会（生命园管委会）、中关村科技园区昌平园管委会、未来城集团、昌发展集 团、生命园公司等十余产业部门联合投资机构、孵化机构组建"赛事服务专班"，为参赛项目提供"一对 一"咨询对接服务，对接昌平区资金扶持、人才引进、产业支持及空间保障等政策。赛事期间，昌平区 还将组织参赛项目团队参观考察中关村生命科学园及重点科研平台，深入了解昌平区产业生态，加速科 技成果转化落地。 昌平区政府党组成员、副区长（兼）赵仕伟介绍，昌平区近年来大力发展医药健康产业，布局构建生命 科学创新走廊，先后出台"产业倍增行动计划"等一系列政策，加快打造具有全球竞争力的生命科学新高 地。目前，"生命谷"聚 ...

Core Viewpoint - The company reported a decline in revenue and net profit for Q1 2025, but showed signs of improvement compared to the previous quarter, with expectations for gradual transformation effects to materialize [1][2]. Financial Performance - In Q1 2025, the company achieved revenue of 1.078 billion yuan, a year-on-year decrease of 20.77% [1]. - The net profit attributable to shareholders was 102 million yuan, down 58.13% year-on-year [1]. - Compared to Q4 2024, the net profit increased by approximately 290 million yuan, and when excluding impairment losses, the net profit rose by about 180 million yuan [2]. Business Segments - The bioactive substances and medical terminal businesses remained stable in Q1 2025, with accelerated R&D, registration, and marketization of new raw materials and pipelines [2]. - The skin science innovation transformation business is still undergoing an adjustment period, prompting the chairman and general manager to take a more hands-on management approach [2]. - The company launched the first Class III medical device for facial skin quality improvement, which is expected to contribute positively to the medical terminal business [2]. Future Outlook - The company anticipates revenue growth for 2025-2027, with projected revenues of 5.774 billion, 6.362 billion, and 7.221 billion yuan, corresponding to growth rates of 7.5%, 10.2%, and 13.5% respectively [3]. - The net profit attributable to shareholders is expected to be 455 million, 530 million, and 628 million yuan for the same period, with growth rates of 161.2%, 16.3%, and 18.7% respectively [3]. - Earnings per share (EPS) are projected to be 0.94, 1.10, and 1.30 yuan per share for 2025-2027 [3].